Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an announcement.
On February 2, 2026, MIRA Pharmaceuticals reported that it has begun dosing the final cohort in its Phase 1 multiple ascending dose trial of Ketamir-2, its lead oral NMDA receptor antagonist, with 50 healthy volunteers already treated and six subjects remaining, and expects to complete the Phase 1 program by the end of the first quarter of 2026. The randomized, double-blind, placebo-controlled study is assessing safety, tolerability and pharmacokinetics, and the company is finalizing a Phase 2a proof-of-concept trial in chemotherapy-induced peripheral neuropathy, which it aims to launch in the second quarter of 2026, reflecting a push into an oncology-related indication with no current FDA-approved therapies and potential pursuit of an expedited regulatory pathway. MIRA also said it will seek partnering opportunities at an industry summit in March 2026 and present Phase 1 data at a major cancer research conference in April 2026, while advancing two preclinical oral programs—SKNY-1 for weight loss and nicotine addiction and MIRA-55 for inflammatory pain—through CMC optimization toward IND-enabling status by year-end 2026, signaling a broadening pipeline and multiple upcoming clinical and business development milestones for stakeholders.
The most recent analyst rating on (MIRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. is a biopharmaceutical company developing small-molecule oral therapeutics targeting neurological, oncologic, metabolic, and inflammatory conditions, including an NMDA receptor antagonist for neuropathic pain, a CB1-focused candidate for weight loss and nicotine addiction, and an analgesic/anti-inflammatory program for pain. Its pipeline is aimed at areas of high unmet medical need, such as chemotherapy-induced peripheral neuropathy and obesity, with an emphasis on differentiated safety profiles versus existing therapies.
Average Trading Volume: 228,281
Technical Sentiment Signal: Sell
Current Market Cap: $51.93M
For a thorough assessment of MIRA stock, go to TipRanks’ Stock Analysis page.